SGLT-2 Inhibitor—Versatile Newcomer in Heart Failure Management

2021 ◽  
Vol 2 (4) ◽  
pp. 193-194
Author(s):  
B. Hygriv Rao
2011 ◽  
Vol 7 (2) ◽  
pp. 104
Author(s):  
Kenneth McDonald ◽  
Ulf Dahlström ◽  
◽  

Heart failure (HF) is characterised by non-specific symptoms and unremarkable physical examination; therefore, the need exists for an available objective marker of HF status. Natriuretic peptides (NPs) are a marker that can aid the dilemmas in present-day HF management. More effective screening for clinical deterioration would include changes in brain natriuretic peptide (BNP) levels. Normal values for BNP, <50–100 pg/ml, have excellent negative predictive value (NPV) in excluding HF as a diagnosis. BNP values that are significantly elevated, e.g. >500 pg/ml, make the diagnosis of HF more likely. There are now established and emerging uses for NPs in managing HF in the community. These include the role of NPs at the time of possible new presentation of HF, its role in prognostication and, finally, the increasing interest in using NPs to guide therapy in the outpatient setting.


2005 ◽  
Vol 60 (2) ◽  
pp. 179-184 ◽  
Author(s):  
Gilles W. DE KEULENAER ◽  
Dirk L. BRUTSAERT

2003 ◽  
Vol 9 (4) ◽  
pp. 263-265 ◽  
Author(s):  
David J. Whellan ◽  
Daniel B. Mark

1999 ◽  
Vol 159 (16) ◽  
pp. 1939 ◽  
Author(s):  
Wendy A. Gattis ◽  
Vic Hasselblad ◽  
David J. Whellan ◽  
Christopher M. O'Connor

2000 ◽  
Vol 16 (3) ◽  
pp. 549-566 ◽  
Author(s):  
Kevin Marzo ◽  
Florence M. Prigent ◽  
Richard M. Steingart

Sign in / Sign up

Export Citation Format

Share Document